According to United States Renal Data System (USRDS) 2003 Annual Data Report, approximately 400,000 end stage renal disease (ESRD) patients were in treatment in 2001. Just under 100,000 of those patients were new to the Medicare ESRD program that year. ESRD program payments in 2001 were approximately 6.4 percent of the 15.4 billion dollars in Medicare spending. Treatment options include hemodialysis, peritoneal dialysis, and transplantation. The majority of ESRD patients are treated in dialysis facilities.
The native arteriovenous (AV) fistula is the preferred type of vascular access for patients with end stage renal disease. Compared to catheters and AV grafts, native AV fistulae result in significantly lower rates of complication (such as infection and clotting), longer patency, fewer hospitalizations, lower patient morbidity, and significantly lower costs.
*********************************************************
Related Information on IHI.org:
Boosting Arteriovenous (AV) Fistula Rates in ESRD Patients
Renal Disease Management Across the Continuum
ESRD Network Program Where Ingrained Habits Are Giving Way to Best Practice